| Literature DB >> 23410164 |
Abstract
Polypharmacology offers a model for the way drug discovery must evolve to develop therapies most suited to treating currently incurable diseases. It is driven by a worldwide demand for safer, more effective, and affordable medicines against the most complex diseases, and by the failures of modern drug discovery to provide these. Polypharmacology can involve combinations and/or multitarget drugs (MTD). Although not mutually exclusive, my premise is that MTDs have inherent advantages over combinations. This review article focuses on MTDs from a medicinal chemistry perspective. I will explore their use in current clinical practice, their likely application in the future, and the challenges to be overcome to achieve this goal.Mesh:
Substances:
Year: 2013 PMID: 23410164 DOI: 10.2174/0929867311320130004
Source DB: PubMed Journal: Curr Med Chem ISSN: 0929-8673 Impact factor: 4.530